Incyte Corp
(NAS:INCY)
$
69.91
0.07 (0.1%)
Market Cap: 13.47 Bil
Enterprise Value: 11.73 Bil
PE Ratio: 499.36
PB Ratio: 4.25
GF Score: 89/100 Incyte Corp at Goldman Sachs Healthcare CEOs Unscripted Conference: A View from the Top (Virtual) Transcript
Jan 06, 2022 / 08:00PM GMT
Release Date Price:
$72.63
(+3.09%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP
Good afternoon, everyone, and thank you for joining us for the Goldman Sachs CEO Unscripted Conference. We're really pleased to have Herve Hoppenot, Chairman, President and CEO of Incyte. Thank you, Herve, for joining us. Happy New Year.
Herve Hoppenot
Incyte Corporation - Chairman, President & CEO
Thank you for inviting me.
Questions & Answers
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP
Thank you. And as we start or stand today -- as you stand today, sorry, with Jakafi, Pemazyre and Monjuvi and recently approved Opzelura and the current pipeline, what is your outlook on the overall business and where you must focus in 2022?
Herve Hoppenot
Incyte Corporation - Chairman, President & CEO
Salveen, thanks for the invitation. So 2022 is very simple. In fact, in many ways, it's about growth of revenue, and we have obviously Jakafi that is growing in its
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot